STAA — STAAR Surgical Company

Is STAA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Overbought As of November 17, 2026

STAAR Surgical Company (STAA) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $26.01. The rating moved from Oversold to Overbought on November 13, 2026.

See all overbought Healthcare stocks →

AI analysis

STAAR Surgical Company (STAA) benefits from a focused, high-value product (ICL) with improving surgeon adoption and demographic tailwinds that support above-market growth potential. The business is exposed to elective-procedure cyclicality, execution on commercial expansion, and regulatory/labeling risk. If procedure volumes continue to recover and international expansion proceeds, the company can exhibit strong operating leverage and margin expansion. Near-term market sensitivity to macro and risk-off flows could create volatility; key monitoring items are procedure mix, ASP trends, inventory/supply stability, and any regulatory or safety developments.

Key factors

  • Growing adoption of EVO ICL platform and strong clinical outcomes driving surgeon preference and patient demand for refractive lens exchange alternatives
  • Exposure to expanding global elective ophthalmic procedures, particularly in key markets (U.S., Japan, Europe) with demographic tailwinds for myopia and presbyopia management
  • Recurring revenue characteristics from procedure-driven consumables and aftermarket services supporting margin improvement as volumes scale
  • Reasonable balance sheet and historical operational leverage potential that can amplify earnings on volume recovery
  • Limited direct competition in the implantable collamer lens niche versus broad LASIK market, providing a defensible product position
  • Near-term catalysts include expanded labeling/indications, geographic expansion, and continued surgeon training/adoption programs

Risks

  • High sensitivity to elective procedure volumes; economic slowdown or risk-off environment can meaningfully reduce near-term revenue
  • Product concentration risk: reliance on a small portfolio (ICL) amplifies impact of any regulatory actions, recalls, or adverse clinical publicity
  • Regulatory and reimbursement uncertainty across markets, including surgical facility access and payer behavior for vision correction procedures
  • Competitive dynamics from laser refractive technology improvements and potential new entrants or OEMs targeting the premium vision correction segment
  • Foreign exchange and supply-chain constraints given international revenue mix and manufacturing complexity
  • Execution risk around commercialization investments, surgeon training conversion rates, and ability to convert trials into recurring procedures

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for STAA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.